Exosome-Carried microRNA-375 Inhibits Cell Progression and Dissemination via XXXX Blocking in Colon Cancer.

@entity1 @entity588 @entity26261 @entity5 @entity4404 @entity2823 @entity14
BACKGROUND AND AIMS: Worldwide, @entity14 ( @entity14 ) is the third most common @entity5 in @entity1 and second in @entity1 . The aim of the current study was to identify whether the @entity26261 is indeed down-regulated in metastatic @entity14 and if it could be considered as a potential minimally invasive prognostic biomarker for @entity14 . METHODS: Exosomes were isolated and characterized from @entity1 with liver metastasis from CCR. The characterization of exosome was performed using TEM/SEM. HCT116 cells were treated with @entity26261 mimic, NSM and @entity26261 inhibitor. Functional assays included cell counting assay for 14 days, Matrigel invasion assay, apoptosis assay by flow cytometry using @entity4404 - @entity2823 , RT-PCR and Western blotting. RESULTS: Increased proliferation potential was proven for the cells transfected with @entity26261 inhibitor, while the @entity26261 mimic decreased the cell number. The cells transfected with the @entity26261 inhibitor are aggressive and cross the membrane; 3.84% of the cells transfected with the @entity26261 inhibitor entered apoptosis, while 6.45% of those transfected with the non-specific mimic were in programmed cell death, less than those transfected with the microRNA. RT-PCR for @entity588 expression showed that @entity588 is down-regulated for @entity26261 inhibitor and up-regulated for the @entity26261 mimic, a result confirmed by Western blotting. CONCLUSION: The present study brings to the forefront new data that suggest @entity26261 as a new player in controlling the pathways responsible for inhibiting the natural history of @entity14 cells, via the @entity588 pathway.
